Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: A comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy

Stroke

Volumn 41, Issue 6, 2010, Pages 1163-1168

  Puato, Massimo ^a   Faggin, Elisabetta ^a   Rattazzi, Marcello ^a   Zambon, Alberto ^b   Cipollone, Francesco ^e   Grego, Franco ^c   Ganassin, Lorenzo ^d   Plebani, Mario ^a   Mezzetti, Andrea ^e   Pauletto, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Dipartimento di Scienze Mediche e Chirurgiche   (Italy)

^c Dipartimento di Scienze Cardiologiche Toraciche e Vascolari   (Italy)

^d OSPEDALE CA FONCELLO   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerosis; Carotid artery; Lipids; Lipoprotein; Macrophages; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; COLESTYRAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITOSTEROL;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; INFLAMMATION; LOW DRUG DOSE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CHOLESTYRAMINE RESIN; ENDARTERECTOMY, CAROTID; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LYMPHOCYTE COUNT; MACROPHAGES; MALE; PYRROLES; SITOSTEROLS;

EID: 77953127955     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.580811     Document Type: Article

References (23)

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24:1329-1330.
2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
4. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
5. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278.
6. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
7. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:1425-1433.
8. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
9. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.
10. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363:2015-2021.
11. Kinlay S. Low-density lipoprotein-dependent and-independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007;49:2003-2009.
12. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001; 103:926-933.
13. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Metaanalysis of cardiovascular outcomes trials comparing intensive vs moderate statin therapy. J Am Coll Cardiol. 2006;48:438-445. (Pubitemid 44109954)
14. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, Spence JD. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North Am Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1998;339:1415-1425.
15. Pauletto P, Puato M, Faggin E, Santipolo N, Pagliara V, Zoleo M, Deriu GP, Grego F, Plebani M, Sartore S, Bon GB, Heymes C, Samuel JL, Pessina AC. Specific cellular features of atheroma associated with development of neointima after carotid endarterectomy: the carotid atherosclerosis and restenosis study. Circulation. 2000;102:771-778.
16. Sartore S, Chiavegato A, Franch R, Faggin E, Pauletto P. Myosin gene expression and cell phenotypes in vascular smooth muscle during development, in experimental models, and in vascular disease. Arterioscler Thromb Vasc Biol. 1997;17:1210-1215.
17. Puato M, Faggin E, Rattazzi M, Paterni M, Kozakova M, Palombo C, Pauletto P. In vivo noninvasive identification of cell composition of intimal lesions: a combined approach with ultrasonography and immu-nocytochemistry. J Vasc Surg. 2003;38:1390-1395.
18. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, Verhagen HJ, Khan NA, Dunkelgrun M, Bax JJ, Poldermans D. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361:980-989.
19. Verhoeven BA, Moll FL, Koekkoek JA, van der Wal AC, de Kleijn DP, de Vries JP, Verheijen JH, Velema E, Busser E, Schoneveld A, Virmani R, Pasterkamp G. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke. 2006;37:2054-2060.
20. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
21. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, Munoz-Garcia B, Vega M, Serrano J, Ortega L, Hernandez G, Tunon J, Egido J. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke. 2005;36:1796-1800.
22. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:2716-2723.
23. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-1193.